Pharmacology, Biochemistry, and Behavior
June 30, 2026
Lucie Ladislavová, Viera Kútna, Kristýna Mazochová et al.
Psilocin (4-hydroxy-N, N-dimethyltryptamine) is a substituted tryptamine alkaloid and a nonselective serotonergic agonist acting predominantly at 5-HT2A/C receptors, with substantial binding to 5-HT1A and 5-HT2B receptors. Microdosing is the practice of taking a very small, sub-perceptual dose, typically 5% to 10% of a full recreational dose, to improve mood, creativity, and focus without...
The International Journal of Neuropsychopharmacology
August 1, 2025
Klára Šíchová, Barbara Mallarino, Lucie Janeckova et al.
1 citation
Hexahydrocannabinol (HHC) is a new psychoactive substance known for its mind-altering effects and temporary legal status. It is widely used in parts of the Europe and United Kingdom as a legal alternative to ∆9-tetrahydrocannabinol, yet little research has explored its effects and safety. This study examined how HHC is processed in the body, its toxicity, and its impact on behavior in male...
European Journal of Pharmacology
July 15, 2025
Isis Koutrouli, Kristýna Mazochová, Rachel R. Horsley
4 citations
Depression affects hundreds of millions globally, and in 2019, esketamine, an S-enantiomer of ketamine, was approved for treatment-resistant depression (TRD). While effective, esketamine carries risks, including abuse potential and adverse effects even at low doses. As a result, ketamine's metabolite, (2R,6R)-hydroxynorketamine ((2R,6R)-HNK), has garnered attention for its potential...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
July 5, 2025
Hynek Danda, Kristýna Mazochová, Klára Šíchová et al.
1 citation
Baeocystin is a naturally occurring tryptamine-based compound found in various psychoactive mushrooms, including in several species of Psilocybe genus. Due to its structural similarity to psilocybin, which has shown a therapeutic potential in treatment of psychiatric disorders, there is a growing interest in investigating whether baeocystin exhibits comparable effects. This study investigated...
The International Journal of Neuropsychopharmacology
February 12, 2025
*Bronislav Jurásek, Magdaléna Vágnerová, Hana Walaská et al.
Abstract Background Methoxphenidine (MXP) is a new psychoactive substance that belongs to the group of arylethylamines. Even though MXP has a different pharmacophore than ketamine, both of these substances belong to the dissociatives. To date, MXP has been associated with several intoxications and despite it being banned in most countries it is still available over the internet.1 Aims &...
October 2, 2024
Klára Šíchová, Barbara Mallarino, Lucie Janeckova et al.
Background and purpose: Hexahydrocannabinol (HHC) is a novel psychoactive substance that has gained attention due to its psychotropic effects and temporary legal status. It is widely abused in several EU and US countries, where it serves as a legal and easily accessible alternative to ∆ 9 -tetrahydrocannabinol (∆ 9 -THC). Despite its widespread use, few studies have examined its in vivo effects...